Form 4: Orchestra BioMed Director Connealy Receives Stock Options and Restricted Stock Units

Director Pamela Ann Connealy of Orchestra BioMed Holdings, Inc. [OBIO] acquired stock options and restricted stock units on June 20, 2024.

Summary

• On June 20, 2024, Pamela Ann Connealy, a director of Orchestra BioMed Holdings, Inc. [OBIO], was granted stock options and restricted stock units (RSUs).
• Connealy acquired 17,068 stock options with an exercise price of $7.44, exercisable from June 20, 2025, and expiring on June 20, 2034.
• She also received 5,376 restricted stock units (RSUs), each representing a contingent right to receive one share of common stock, vesting on June 20, 2025.
• Following these transactions, Connealy directly owns 21,289 shares of common stock and 17,068 stock options.

Sentiment

Score: 6

Explanation: The document is a routine SEC filing related to stock options and RSU grants, which is generally neutral. The grants can be seen as a positive sign of incentivizing the director, but it's not a major market-moving event.

Positives

• The granting of stock options and RSUs to a director aligns their interests with those of the shareholders, potentially incentivizing them to work towards the company's success.
• The vesting schedule of the RSUs (June 20, 2025) encourages long-term commitment from the director.

Industry Context

Stock options and restricted stock units are common forms of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with those of shareholders. The size and terms of the grants are generally benchmarked against peer companies.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in publicly traded companies, particularly in the biotech sector.
• The vesting period of one year for the RSUs is fairly typical, as it encourages continued service to the company.
• The exercise price of $7.44 for the stock options would need to be compared to the market price of OBIO stock at the time of the grant to determine if it is at-the-money, in-the-money, or out-of-the-money.
• Comparable companies in the biotech space, such as Medtronic or Boston Scientific, also utilize stock options and RSUs as part of their executive compensation plans.

Stakeholder Impact

• The granting of stock options and RSUs could potentially increase shareholder value if the director's performance improves the company's financial results.
• Employees may view the grants as a positive sign of the company's commitment to its leadership.

Key Dates